Product Information
LEVOCARNITINE 330 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.6433 per EA under NDC 16571076209. Its NADAC has been published 151 times since Aug 9, 2023.
Strength
330 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571076209
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
LEVOCARNITINEApproval Type
Generic (ANDA)
FDA Application
ANDA076858On Market Since
12/1/2020
Pharmacological Classes
Price Statistics
The NADAC for LEVOCARNITINE 330 MG TABLET has been published 151 times since Aug 9, 2023, and over the history we have for it it has declined 21.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6433 per EA |
|---|---|
| All-time high | $0.8677 (Jan 10, 2024) |
| All-time low | $0.4863 (Jul 17, 2024) |
| 52-week high | $0.7556 |
| 52-week low | $0.6433 |
| Median price | $0.7177 |
| Average price | $0.7187 |
| Largest weekly change | -31.3% (Apr 17, 2024) |
| Weeks tracked | 151 |
| Tracking since | Aug 9, 2023 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of LEVOCARNITINE 330 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LEVOCARNITINE 330 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.6433 per EA (NDC 16571076209), effective Jun 24, 2026.
How has the price of LEVOCARNITINE 330 MG TABLET changed over time?
Over the history we have for it, the NADAC for LEVOCARNITINE 330 MG TABLET has declined 21.8%. It has been tracked across 151 weekly CMS publications since Aug 9, 2023.
What are the highest and lowest recorded NADAC prices for LEVOCARNITINE 330 MG TABLET?
Since Aug 9, 2023, the NADAC for LEVOCARNITINE 330 MG TABLET has ranged from a low of $0.4863 (Jul 17, 2024) to a high of $0.8677 (Jan 10, 2024), with a median of $0.7177 per EA.
Are there cheaper alternatives to LEVOCARNITINE 330 MG TABLET?
1 NADAC-published product shares the same active ingredient, strength, and dosage form as LEVOCARNITINE 330 MG TABLET, but none are currently priced below it.
Who manufactures LEVOCARNITINE 330 MG TABLET?
LEVOCARNITINE 330 MG TABLET (NDC 16571076209) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification